Details for Patent: 11,878,049
✉ Email this page to a colleague
Which drugs does patent 11,878,049 protect, and when does it expire?
Patent 11,878,049 protects PYRUKYND and is included in one NDA.
Drugs Protected by US Patent 11,878,049
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-001 | Feb 17, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS | ⤷ Sign Up | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-002 | Feb 17, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS | ⤷ Sign Up | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-003 | Feb 17, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
